Analyst Price Targets — INFU
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 8:17 pm | — | Roth Capital | $15.00 | $8.60 | TheFly | InfuSystem price target raised to $15 from $14 at Roth Capital |
| November 4, 2025 8:12 pm | — | Roth Capital | $14.00 | $9.48 | TheFly | InfuSystem price target raised to $14 from $13 at Roth Capital |
Latest News for INFU
My coverage for InfuSystem continues, focusing on recent developments and strategic positioning. INFU has made key operational improvements, has solid growth initiatives, and has the potential for continued strong revenue and earnings gains. InfuSystem's above-average growth has the potential to drive the stock for above-average long-term gains.
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026.
InfuSystem (NYSE: INFU - Get Free Report) and Nemaura Medical (OTCMKTS:NMRD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability. Profitability This table compares InfuSystem and Nemaura Medical's net
InfuSystem Holdings, Inc. (INFU) Q4 2025 Earnings Call Transcript
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INFU.
U.S. House Trading
No House trades found for INFU.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.